SiTime Corporation (SITM) Stock Price Today
Aura AI Summary
Key Stats
- $18.41BMarket Cap
- -Volume
- TechnologySector
- $901.6052W High
- $234.7752W Low
- -Typical Hold Time
- $17.81BEnterprise Value
- -Div Yield
- -Trading Activity
Track SiTime Corporation (SITM) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, SiTime Corporation has traded between a low of $234.77 and a high of $901.6, highlighting its annual price range. Buy and sell SiTime Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Most Recent News
Core Scientific director Elizabeth Crain buys 6,000 shares, signaling confidence in the company.
Elizabeth Crain, a director at Core Scientific, has purchased 6,000 shares of the company. This insider buying may indicate her confidence in the company's future prospects. Such moves often attract investor attention as they can signal positive expe...

Hyperscale Data shifts to AI data centers, signals undervaluation and insider confidence
Hyperscale Data has stopped Bitcoin mining to focus on AI data center services, backed by a $1.2 billion contract at its Michigan facility. The company's assets, including cash and Bitcoin, are worth nearly double its market cap, suggesting undervalu...

Pharvaris stock jumps after positive HAE drug trial and Oppenheimer raises price target to $75
Pharvaris's experimental oral drug deucrictibant showed an 83% reduction in hereditary angioedema (HAE) attacks in a Phase 3 trial, prompting Oppenheimer to raise its price target from $50 to $75 and maintain an "Outperform" rating. The positive tria...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.